Step 1 Hematology and Oncology

Hematology and Oncology is one of the most heavily tested areas on USMLE Step 1, covering RBC disorders, WBC malignancies, bleeding and clotting pathology, and cancer pharmacology. These topics appear both as standalone one-liners (identify the anemia from the iron panel, name the mutation in CML) and as full clinical vignettes requiring you to integrate symptoms, labs, and smear findings into a diagnosis and treatment plan. If you are reviewing high-yield hematology topics for Step 1, the iron panels and coagulation cascades below are where the most questions cluster.

The anemia section rewards systematic triage: MCV first, then reticulocyte index, then disease-specific confirmatory tests. Hemostasis questions hinge on correctly separating platelet disorders from coagulation factor deficiencies, then drilling into specific diseases like TTP, HIT, or hemophilia. Students consistently reverse TIBC in iron-deficiency anemia — TIBC goes up when iron is low, not down — and confuse which coagulation pathway maps to PT versus PTT. Those lab-pattern errors are where most points are lost.

Step 1 oncology questions tend to test translocations and their targeted therapies (BCR-ABL to imatinib, APL to ATRA), classic smear or biopsy findings (Reed-Sternberg cells, Auer rods, smudge cells), and drug toxicity profiles. Another common misconception: students assume ATRA works as a cytotoxic agent, when it actually differentiates the leukemic promyelocytes. USMLE chemotherapy pharmacology is almost always tested as a toxicity question — know the signature adverse effect and any specific rescue agent for each class.